Table 3.
Baseline characteristics of subjects with follow-up by treatment modality
| Medical management (n=69) | Endoscopic sinus surgery (n=273) | ||||
|---|---|---|---|---|---|
| Demographics: | Mean (SD) | N(%) | Mean (SD) | N (%) | p-value |
| Follow-up duration (months) | 12.8 (5.6) | 13.4 (5.6) | 0.398 | ||
| Age (years) | 52.0 (13.8) | 52.2 (14.6) | 0.937 | ||
| Males | 28 (40.6) | 127 (46.5) | --- | ||
| Females | 41 (59.4) | 146 (53.5) | 0.376 | ||
| White / Caucasian | 58 (84.1) | 231 (84.6) | 0.909 | ||
| Hispanic / Latino | 1 (1.4) | 16 (5.9) | 0.213 | ||
| Education (years) | 15.9 (2.6) | 15.0 (2.8) | 0.014 | ||
| Clinical characteristics: | |||||
| Asthma | 21 (30.4) | 101 (37.0) | 0.309 | ||
| Allergies (skin prick / RAST confirmed) | 27 (39.1) | 102 (37.4) | 0.787 | ||
| ASA sensitivity | 8 (11.6) | 23 (8.4) | 0.413 | ||
| Depression | 13 (18.8) | 48 (17.6) | 0.807 | ||
| Tobacco use/current smoker | 1 (1.4) | 15 (5.5) | 0.211 | ||
| Alcohol consumption | 36 (52.2) | 123 (45.1) | 0.289 | ||
| COPD | 3 (4.3) | 13 (4.8) | >0.999 | ||
| Steroid dependency | 3 (4.3) | 19 (7.0) | 0.587 | ||
| Previous sinus surgery | 40 (58.0) | 142 (52.0) | 0.376 | ||
| Nasal polyposis | 27 (39.1) | 105 (38.5) | 0.919 | ||
| Septal deviation | 15 (21.7) | 119 (43.6) | 0.001 | ||
| Hypertrophy turbinate | 5 (7.2) | 42 (15.4) | 0.115 | ||
| Clinical disease severity measures: | |||||
| SNOT-22 total score | 44.3 (18.9) | 53.6 (18.8) | <0.001 | ||
| Computed tomography score | 13.3 (6.0) | 12.3 (6.0) | 0.265 | ||
| Endoscopy score | 6.6 (4.0) | 6.2 (3.8) | 0.426 | ||
SD, standard deviation; RAST, radioallergosorbent; ASA, acetysalicyclic acid; COPD, chronic Obstructive pulmonary disease; SNOT-22, 22-item SinoNasal Outcome Test